Aubrai Launches on Base, Using AI and Blockchain to Revolutionize Longevity Science
Aubrai, a decentralized science (DeSci) and artificial intelligence agent, has launched on Base, aiming to reshape longevity research by combining blockchain infrastructure with cutting-edge biomedical science. Built by VitaDAO and Bio Protocol in collaboration with Aubrey de Grey’s LEV Foundation, the project leverages unpublished data from de Grey’s lab to generate and fund novel anti-aging experiments.
At the heart of Aubrai is the AUBRAI token, launched via Bio Protocol’s Launchpad. Token holders gain governance rights over research decisions and share in the revenue from discoveries that are successfully commercialized, turning scientific breakthroughs into investable digital assets.
Bridging the ‘Valley of Death’ in Longevity Research
Aubrai’s core mission is to address the “valley of death”—the funding gap where promising long-term discoveries falter due to lack of market-ready capital. By tokenizing research outputs and using DAOs to fund experiments directly, Aubrai bypasses the limitations of traditional venture capital and philanthropic models.
“Conventional funding models leave longevity research stranded between discovery and clinical application,” said Aubrey de Grey, who is widely known for his SENS (Strategies for Engineered Negligible Senescence) framework. “Aubrai introduces mechanisms that can crowdsource risk and align incentives toward societal benefit.”
AI Meets Onchain Science
Aubrai combines proprietary lab research with AI-driven hypothesis generation. The agent ingests experimental data into a structured knowledge graph, proposes new hypotheses, and routes them to AUBRAI token holders for funding votes. Once validated, these discoveries are minted as IP tokens, which can be licensed to biotech and pharmaceutical companies—with proceeds distributed to contributors.
The system is already integrated into de Grey’s Robust Mouse Rejuvenation (RMR2) study, one of the most ambitious longevity experiments to date. Aubrai has been credited with flagging dosing concerns and suggesting design improvements that would have otherwise required weeks of manual review.
Reimagining Science as a Creator Economy
Paul Kohlhaas, founder of Bio Protocol, likens Aubrai’s impact to that of platforms like Substack for writers. “We’re building infrastructure that allows scientists to become the next generation of creators—funded by their communities and rewarded for their discoveries,” he said.
DeSci’s Road Ahead
While the potential of DeSci is clear, challenges remain. Regulatory scrutiny around tokenized IP is likely, and institutional players may hesitate to adopt findings emerging from decentralized collectives.
Still, Aubrai’s success could demonstrate that blockchain is capable of more than speculative finance—it could become a core layer for funding and accelerating real-world innovation. If it succeeds, Aubrai may not just extend human health span but also redefine how science is conducted and capitalized in the 21st century.
